Filing Details

Accession Number:
0001179110-17-013875
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-11-08 16:21:44
Reporting Period:
2017-11-06
Accepted Time:
2017-11-08 16:21:44
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1597264 Blueprint Medicines Corp BPMC Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1638468 L. Anthony Boral C/O Blueprint Medicines Corporation
38 Sidney Street, Suite 200
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-11-06 5,000 $8.80 5,000 No 4 M Direct
Common Stock Disposition 2017-11-06 200 $74.00 4,800 No 4 S Direct
Common Stock Disposition 2017-11-06 200 $72.87 4,600 No 4 S Direct
Common Stock Disposition 2017-11-06 700 $71.69 3,900 No 4 S Direct
Common Stock Disposition 2017-11-06 1,520 $70.29 2,380 No 4 S Direct
Common Stock Disposition 2017-11-06 2,380 $69.59 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2017-11-06 5,000 $0.00 5,000 $8.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
169,544 2025-02-10 No 4 M Direct
Footnotes
  1. The exercise reported on this Form 4 was effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
  2. The sales reported on this Form 4 were effected pursuant to a trading plan adopted on December 17, 2016 pursuant to Rule 10b5-1 under the Exchange Act.
  3. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.85 to $74.15 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) through (7) to this Form 4.
  4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.49 to $73.25 per share.
  5. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.20 to $72.14 per share.
  6. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.03 to $70.81 per share.
  7. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.98 to $69.91 per share.
  8. This option was granted on February 10, 2015. This option vested with respect to 25% of the shares underlying the option on February 9, 2016 and as to an additional 1/48th of the shares underlying the option each month thereafter.